Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion

Phase 1positiveR-5780Positive

AI Analysis

Summary

Rise Therapeutics announced completion of dose escalation in its Phase 1 trial of R-5780, an oral immunotherapeutic candidate for cancer, and is advancing to dose expansion. The trial progression represents typical clinical development progress for a clinical-stage company.

Clinical Trial Data

Phase

Outcome Details

Completed dose escalation portion and advancing to dose expansion

Importance:5/10

Sentiment:

0.70

Phase 1oncologyimmunotherapydose escalationclinical development

Read the original article

Published by PR Newswire Biotech on September 22, 2026 1:07 PM

Read Original